Community-based Microalbuminuria Screening in Patients With Hypertension

Effectiveness of Different Antihypertensive Medications on Urine Albumin-to-Creatinine Ratio (UACR) in Community Hypertensive Patients With Microalbuminuria

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03596840

Acronym

CMSIH

Enrollment

3000

Registered

2018-07-24

Start date

2018-08-01

Completion date

2020-12-31

Last updated

2018-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Microalbuminuria

Keywords

Hypertension, Microalbuminuria, Effectiveness, Antihypertensive medications

Brief summary

This study evaluates the effectiveness of different anti-hypertensive drugs on patients with hypertension and microalbuminuria.

Detailed description

This is a a real world registry study. All patients with hypertension in community hospitals in China will be eligible . Patient demographics, medical history, clinical characteristics, physical examination, laboratory tests (including UCAR, blood routine, urine routine, blood biochemistry, and ECG), antihypertensive drugs (including: ACEI/ ARB, thiazide diuretics, CCB, beta-blockers, alpha-blockers, and other antihypertensive drugs used in real-life clinical practice in other communities.) will be recorded. All patients are anticipated to be followed up for 12-month. Effectiveness of different antihypertensive medications on Urine Albumin-to-Creatinine Ratio (UACR) will be evaluted.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with essential hypertension; * Urinary albumin/creatinine ratio in random urine samples is 30-300 mg/g * Age \>=18 * Understand and sign informed consent

Exclusion criteria

* This is a real-world registry study and does not set

Design outcomes

Primary

Measure	Time frame	Description
Urine Albumin-to-Creatinine Ratio (UCAR)	12 months	Differences in UCAR between with ACEI/ARB and without ACEI/ARB

Secondary

Measure	Time frame	Description
Combined endpoints: re-admission, cardiovascular events, and all-cause mortality	12 months	Differences in Combined endpoints between with ACEI/ARB and without ACEI/ARB

Contacts

Primary ContactXuejuan Jin, MS

jin.xuejuan@zs-hospital.sh.cn+86-13681973269

Backup ContactWei Zhang, phD

+86-13917535963

Outcome results